Early Plasma Circulating Tumor DNA as a Potential Biomarker of Disease Recurrence in Non-metastatic Prostate Cancer

Abstract

In non-metastatic prostate cancer (nmPCa) setting, it is important to early identify the patients at risk of biochemical recurrence (BCR) for immediate postoperative intervention. Our study aimed to evaluate the potential clinical utility of circulating tumor DNA (ctDNA) for predicting disease recurrence. Materials and MethodsThis real-world observational study evaluated 161 cases of nmPCa undergoing next-generation sequencing at our institution. A total of 139 ctDNA samples and 31 biopsied tumor tissue underwent genomic profiling. The study endpoint was BCR after radical prostatectomy.Relationships between the ctDNA status and the biochemical progression-free survival (bPFS) were analyzed by log-rank test and multivariate Cox regression. ResultsOf 161 enrolled patients, 19(11.8%) harbored deleterious alterations in NCOR2, followed by BRCA2(3.7%), ATR(2.5%) and CDK12(2.5%). Of available pre-operative blood samples(n=139), ctDNA was detectable in 91(65.5%). Until last follow-up, 56 of 68(85.3%) patients with detectable ctDNA had achieved BCR, whereas only 8 of 39(20.5%) patients with undetectable ctDNA had achieved BCR. Patients who had undetectable ctDNA experienced

Circulating Tumor DNA Is a Variant of Liquid Biopsy with Predictive and Prognostic Clinical Value in Breast Cancer Patients

“…Thus, using the example of patients with colorectal cancer, the potential clinical significance of ctDNA determination was shown for the first time. ctDNA can be found in many types of cancer, including BC [79], lung cancer [80], colorectal cancer [81], prostate cancer [82], gastric cancer [83], ovarian cancer [84], and others [85][86][87][88][89]. It has also been shown that ctDNA can be detected in early-stage cancer patients, while the most characteristic change in cancer patients is DNA hypermethylation.…”

“…Most of these studies have been carried out on lung cancer [80,[99][100][101][102] and colorectal cancer [81,103], including the use of DNA methylation analysis [104]. However, other types of cancer, such as ovarian cancer [84], prostate cancer [82,105], pancreatic ductal adenocarcinoma [106], melanoma [107], and others [88,89,[108][109][110], have also been widely represented in the works carried out in recent years.…”